Bharat Biotech and Bilthoven Biologicals B.V. Announce Collaboration to Produce and Supply Oral Polio Vaccines
A requisite Agreement has been signed between BBIL and BBio wherein BBIL will procure drug substances for the production of oral polio vaccines to be supplied within India and globally.
Bharat Biotech, a global leader in vaccine and biotherapeutic innovation, and also the largest manufacturer of oral polio vaccines, and Bilthoven Biologicals B.V., (BBio), a wholly owned subsidiary of Serum Institute of India Private Limited, based in the Netherlands, announced a collaboration today, to further strengthen the production and supply security of Oral Polio Vaccines (OPV).
A requisite Agreement has been signed between BBIL and BBio wherein BBIL will procure drug substances for the production of oral polio vaccines to be supplied within India and globally.
Read Also : Indian Institute of Corporate Affairs organised Roundtable consultationThrough this collaboration, BBIL and BBio will jointly obtain the regulatory approvals and licenses required to commercially manufacture OPVs in India for global supplies from drug substances manufactured in the Netherlands at Bilthoven Biologicals.
Read Also : HAL Q4 results, net profit up by 52.2 percent YoY
News Must Read
- GAIL India Q4 results, 22 percent fall in net profit
- MOIL Registers historical performance in FY'24
- PFC Q4 results, PAT jumps 20% YoY to Rs 5,624 cr
- CBI arrests Addl. General Manager of MIDHANI, Hyderabad in Bribery Case
- DHFL Scam: India's Biggest Banking Scam
- CONCOR CMD Interacts with Cold Chain Logistics industry leaders based in Japan
- Harsh Baweja takes charge as Director (Finance), REC Limited
- Cochin Shipyard Limited secured a Large order from a European Client
- Karur Vysya Bank announces Q4 Results: Registers 45% Growth in Net Profit
- PSU stocks on way to announce IPO for their green energy segment